Skip to main content

Advertisement

Table 1 Comparison of clinico-pathological characteristics between patients with de novo and acquired resistance to 1st line endocrine therapy

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

  Acquired resistance de novo resistance
Total = 223 (100%) To 1st line To 1st line
CB (Clinical Benefit) 159 (71.3%) 64 (28.7)
Median duration of treatment in months 15.7+ 2.9
Median Age (Range) at metastasis in years 63.5 (30–89) 61.5 (32–87)
DFI (months) 58.0 (0–294) 36.5 (0–324)
Median Age (Range) at primary cancer in years 56.0 (26–86) 55.0 (28–87)
Maximum Size (Range) of tumour in mm. 24 (4–110) 27 (10–110)
Minimum Size (Range) of tumour in mm. 20 (2–70) 25 (10–75)
Histological lymph node stage(no. of positive nodes) 1 (0) 39.8 1 (0) 37.5
  2 (1–3) 41.8 2 (1–3) 37.5
  3 (≥4) 18.4 3 (≥4) 25.0
Grade (Elston/Ellis) 1 11.6 1 9.3
  2 49.3 2 37.0
  3 30.4 3 40.7
  unknown 8.7 unknown 13.0
Vascular invasion 44.1% 50.0
Bony metastasis 61.5 60.3
Lung metastasis 21.4 23.9
Pleural metastasis 25.5 47.8
Lymphangitis 2.1 15.2
Liver metastasis 10.4 41.8
Other metastasis 35.2 28.8
  1. + = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; DFI = Disease free interval